Cenicriviroc

Algernon Secures Key Patent for Breakthrough Kidney Disease Drug Showing 50% Better Results

Algernon Pharmaceuticals received USPTO patent allowance for Repirinast in kidney disease treatment, valid through 2038. Repirinast showed 50.6% fibrosis reduction, outperforming other treatments. The CKD market is projected to grow to $109.95 billion by 2030. Patents held in Japan and China, with applications pending in Europe and Canada.

In 2020, 65 RCTs in Germany aimed to investigate COVID-19 treatments or preventive interventions, planning to include 20,696 participants from Germany. However, only 13.4% of the target sample size was recruited, with a median of 15 participants per trial. Most trials focused on drug treatments, with a significant portion funded by industry. Despite public investment, recruitment challenges and the impact of the pandemic on healthcare systems limited participation in COVID-19 research in Germany.

Algernon Secures Key Patent for Breakthrough Kidney Disease Drug Showing 50% Better Results

Clinical trial research on COVID-19 in Germany

Related Clinical Trials:

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Adaptive COVID-19 Treatment Trial (ACTT)

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Sarilumab COVID-19

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

A Study of Baricitinib (LY3009104) in Participants With COVID-19

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation

Telemedicine in Outpatient Covid-19 Patients

GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia

Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19

Hamburg Edoxaban for Anticoagulation in COVID-19 Study

Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)

Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

Hydroxychloroquine for COVID-19

Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation

Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19

Test and Treat COVID 65plus+

Drug Development Updates